查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1948958

洛诺昔康片市场按剂量、适应症、最终用户和包装类型划分，全球预测（2026-2032年）

Lornoxicam Tablets Market by Dosage Strength, Indication, End User, Packaging Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年洛诺昔康片剂市值为 8.2545 亿美元，预计到 2026 年将成长至 8.7071 亿美元，预计到 2032 年将达到 11.8547 亿美元，复合年增长率为 5.30%。

主要市场统计数据
基准年 2025 8.2545亿美元
预计年份：2026年 8.7071亿美元
预测年份：2032年 11.8547亿美元
复合年增长率 (%) 5.30%

重点策略性介绍，阐述洛诺昔康片剂的临床特征、剂量注意事项、监管介面和商业性影响。

洛诺昔康片是临床上重要的非类固醇抗发炎药物选择，因其在发炎性和退化性肌肉骨骼疾病治疗中的作用而日益受到关注。本介绍将洛诺昔康置于治疗环境中，阐述其药理特性和耐受性考量与临床医师、药师和采购团队的需求之间的关联。文章强调了了解其製剂、给药途径和监管环境对于有效将其纳入治疗通讯协定的重要性。

监管协调、分销模式转变以及相关人员期望的变化所带来的策略影响正在重塑洛诺昔康片剂市场格局。

受监管政策日益明朗、分销管道偏好转变以及对供应链韧性日益重视等因素的影响，洛诺昔康片剂的市场环境正经历着变革性的转变。监管机构正逐步协调安全监测要求和核准后监管实践，这提高了药物监测专案和生命週期管理的标准。同时，随着数位化药房的日益普及和对机构采购的持续依赖，分销模式也在不断演变，迫使生产商重新评估其通路策略和支援模式。

对不断变化的美国关税制度对洛诺昔康片剂相关人员的采购、物流和商业策略的影响全面评估

美国近期关税政策的调整为包括洛诺昔康片在内的药品生产商、进口商和经销商带来了累积。关税调整会影响整个供应链的到岸成本计算、采购决策和合约谈判。因此，企业被迫寻求供应商多元化、优化物流路线并重新评估库存策略，以降低额外关税及其相关行政负担。

一个详细的细分框架，将剂量、适应症、分销管道和最终用途包装联繫起来，以指导临床和商业性优先排序。

对洛诺昔康片剂进行有效的市场区隔分析，依赖具有临床意义和商业性可行性的细分市场，这些细分市场能够反映产品的生产、分销和实际使用情况。基于剂量强度，本研究分析了4毫克和8毫克两种剂量规格的市场，并以此为基础探讨了製剂模式、依从性以及每种剂量规格的适用临床场景。这些剂量差异会影响包装选择、分发流程以及在急诊环境中的患者咨询程序。

区域趋势和市场进入因素（美洲、欧洲、中东和非洲、亚太地区）驱动差异化的策略方法

区域趋势将对洛诺昔康片的监管管道、供应链设计和商业性策略产生重大影响。在美洲，市场进入受到支付方环境多元化、药品监测要求严格以及公共和私人采购流程混合等因素的影响，因此需要製定个人化的打入市场策略并提供明确的治疗价值证据。该地区的经销管道也多种多样，从集中式医院采购到强大的零售药房网络，因此需要差异化的合作模式和物流模式。

竞争对手的行为和差异化因素受到对临床证据、分销管道优化和供应链韧性策略投资的影响。

在洛诺昔康片剂领域，各公司的竞争地位体现在对临床证据、法规遵循、经销伙伴和生产柔软性的投入。主要企业强调完善的药物监测系统和清晰的标籤，以支持跨适应症的安全用药。他们也推行通路专属策略，与医院采购部门、零售连锁店和数位药局平台建立合作关係，以确保多通路覆盖，并保障在医疗点的产品供应。

为确保洛诺昔康片剂的可及性、合规性和提高其使用率，向商业、监管和供应链领导者提出的实用建议

产业领导者可以采取实际行动来增强自身竞争优势，并确保洛诺昔康片剂的持续供应。首先，应将药物安全监测和监管策略与产品生命週期中的关键节点结合，以预先应对安全性问询并有助于维护药品标籤。这种积极主动的做法将缩短监管机构要求的解决时间，并有助于赢得医疗保健采购者和临床医生的信任。

为了确保分析的严谨性，我们采用了稳健的混合方法调查方法，该方法融合了关键相关人员的见解、二手证据综合和跨部门检验。

本研究采用混合方法，整合了定性一手访谈、二手文献综述和跨部门检验，以全面了解洛诺昔康片剂的情况。一手资讯包括与临床医生、医院药剂师、采购负责人和分销商的结构化访谈，旨在揭示营运挑战、配製原因和分销偏好。这些观点与监管文件、临床文献和已发布的政策指南进行三角验证，以确保事实准确性和情境相关性。

策略整合强调将临床证据、区域差异和营运韧性相结合，以指导洛诺昔康片剂的决策。

总之，洛诺昔康片剂目前的市场状况需要一种整合临床证据、监管准备、分销策略和供应链韧性的综合方法。相关人员整合药理知识、切实可行的经销计画和适应性强的商业模式，将更有能力满足临床医师的期望和病患的需求。策略性的包装和剂量考量，以及在医院、线上和零售通路进行的针对性推广活动，可能会影响药物的使用模式并促进合理用药。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 洛诺昔康锭剂市场按剂量划分

  • 4mg
  • 8mg

9. 洛诺昔康锭剂市场依适应症划分

  • 僵直性脊椎炎
  • 骨关节炎
  • 类风湿性关节炎

第十章 洛诺昔康片剂市场（依最终用户划分）

  • 诊所
  • 居家照护设施
  • 医院

第十一章 洛诺昔康锭剂市场按包装类型划分

  • 泡壳
  • 瓶子

第十二章 洛诺昔康锭剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 洛诺昔康锭市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国洛诺昔康锭剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国洛诺昔康锭市场

第十六章：中国洛诺昔康锭剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ambica Pharma
  • AstraZeneca Pharma India Ltd
  • Aurobindo Pharma
  • Bayer AG
  • Biodef Health Care Private Limited
  • Cipla Ltd
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals
  • IPCA Laboratories Ltd
  • Johnlee Pharmaceuticals Pvt. Ltd.
  • Laurus Labs Ltd
  • Lupin Ltd
  • Ocean Pharmaceutical
  • Orley Laboratories Pvt Ltd
  • Pfizer Ltd
  • Ronak Lifecare Pvt Ltd
  • Sandoz International GmbH
  • Shreeji Pharma International
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-4F7A6D4FB90A

The Lornoxicam Tablets Market was valued at USD 825.45 million in 2025 and is projected to grow to USD 870.71 million in 2026, with a CAGR of 5.30%, reaching USD 1,185.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 825.45 million
Estimated Year [2026] USD 870.71 million
Forecast Year [2032] USD 1,185.47 million
CAGR (%) 5.30%

A focused strategic introduction connecting clinical characteristics, dosing considerations, regulatory touchpoints, and commercial relevance of lornoxicam tablets

Lornoxicam tablets represent a clinically relevant option within nonsteroidal anti-inflammatory therapy, notable for their role in managing inflammatory and degenerative musculoskeletal conditions. This introduction situates lornoxicam within the therapeutic landscape, connecting pharmacologic properties and tolerability considerations to the needs of clinicians, pharmacists, and procurement teams. It emphasizes the importance of understanding formulation, dosing paradigms, and regulatory pathways to effectively integrate the product into treatment protocols.

As the clinical imperative to balance analgesic efficacy with patient safety continues to shape prescribing practices, stakeholders require a clear synthesis of evidence and market dynamics. This section provides that synthesis by describing the drug's mechanism of action, typical dosing considerations, and the contexts in which oral tablet formulations are preferred. It also outlines the competitive environment insofar as it affects formulary decisions and procurement strategies, highlighting that therapeutic positioning depends not only on clinical performance but also on supply reliability, packaging format suitability, and distribution channel accessibility.

In closing, this introduction prepares readers to interpret subsequent sections by aligning clinical attributes with commercial realities. It thereby sets expectations for data-driven discussion on segmentation, regulatory and tariff impacts, regional nuances, and strategic imperatives for manufacturers and distributors operating in the lornoxicam tablet space.

Strategic implications of regulatory harmonization, shifting distribution models, and evolving stakeholder expectations reshaping the lornoxicam tablet landscape

The landscape for lornoxicam tablets is undergoing transformative shifts driven by regulatory clarifications, evolving channel preferences, and heightened attention to supply-chain resilience. Regulatory authorities are increasingly harmonizing safety-monitoring requirements and post-authorization surveillance practices, which raises the bar for pharmacovigilance programs and lifecycle management. Concurrently, distribution models are evolving as digital pharmacy adoption grows alongside enduring reliance on institutional procurement, prompting manufacturers to reassess channel strategies and support models.

Patient expectations and clinician prescribing behavior are also shifting. There is greater emphasis on tolerability profiles and convenient dosing regimens, which affect product development priorities and messaging. Packaging innovations that improve adherence and reduce medication errors are gaining attention, while sustainability considerations are starting to influence procurement decisions across public and private purchasers. These developments intersect with broader healthcare trends such as value-based care and integrated care pathways, driving demand for robust evidence linking therapeutic outcomes to economic and operational benefits.

Taken together, these transformative shifts require agile strategic responses from manufacturers, distributors, and payers. Early recognition of regulatory trajectories, channel evolution, and stakeholder preferences will be instrumental in translating clinical value into durable access and uptake for lornoxicam tablet offerings.

Comprehensive assessment of how evolving United States tariff measures affect sourcing, logistics, and commercial strategies for lornoxicam tablet stakeholders

Recent tariff policy changes enacted by the United States have created a cumulative set of considerations for manufacturers, importers, and distributors of pharmaceutical products, including lornoxicam tablets. Tariff adjustments influence landed cost calculations, sourcing decisions, and contractual negotiations across the supply chain. As a result, companies must reassess supplier diversification, logistics routing, and inventory strategies to mitigate exposure to incremental duties and related administrative burdens.

In practice, tariff-driven cost pressures may incentivize regional production strategies or nearshoring initiatives to reduce dependence on higher-tariff import lanes. Procurement teams are increasingly incorporating tariff scenarios into supplier evaluations and total landed cost models, and legal and compliance teams are updating documentation and classification practices to ensure tariff codes align with product composition and packaging. Moreover, tariff uncertainty can affect pricing negotiations with supply chain partners and customers, making transparent cost pass-through mechanisms and contractual flexibility more important than before.

Importantly, organizations that proactively integrate tariff impact analysis into commercial planning and supply continuity frameworks are better positioned to protect margin, maintain service levels, and respond to policy shifts. Cross-functional coordination between regulatory affairs, supply chain, commercial, and finance functions is essential to translate tariff awareness into durable operational adaptations for lornoxicam tablet distribution and sales in affected markets.

In-depth segmentation framework linking dosage, indication, distribution channels, end-use settings, and packaging to inform clinical and commercial prioritization

Effective segmentation analysis for lornoxicam tablets hinges on clinically meaningful and commercially actionable divisions that reflect how the product is manufactured, distributed, and used in practice. Based on Dosage Strength, the market is studied across 4 Mg and 8 Mg, which informs discussions about prescribing patterns, adherence, and the clinical scenarios where each strength is preferred. These dosing distinctions have implications for packaging choices, dispensing workflows, and patient counseling protocols in both acute and chronic care settings.

Based on Indication, the market is studied across Ankylosing Spondylitis, Osteoarthritis, and Rheumatoid Arthritis, enabling detailed alignment of clinical evidence and therapeutic positioning with the unmet needs of each patient population. Indication-driven segmentation allows manufacturers to prioritize evidence generation, medical affairs engagement, and targeted clinician education that address the distinct symptomatology and treatment pathways associated with these conditions. Patient demographics and comorbidity patterns within each indication also shape safety messaging and risk mitigation strategies.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is further studied across Government Hospital Pharmacy and Private Hospital Pharmacy. The Online Pharmacy is further studied across Mobile Application and Website. The Retail Pharmacy is further studied across Chain Pharmacy and Independent Pharmacy. This layered channel framework clarifies where investments in cold chain, digital services, point-of-care education, and contract negotiations will deliver the greatest return, while also highlighting operational constraints faced by each channel type.

Based on End User, the market is studied across Clinics, Home Care Settings, and Hospitals, which underscores the divergent logistical and support requirements for each endpoint of care. Based on Packaging Type, the market is studied across Blister Packs and Bottles, a distinction that informs adherence strategies, regulatory labeling approaches, and patient-facing communications. Together, these segmentation lenses provide a multidimensional view that stakeholders can use to prioritize portfolio decisions, distribution investments, and field engagement plans.

Regional dynamics and market access considerations across the Americas, Europe Middle East Africa, and Asia-Pacific that drive differentiated strategic approaches

Regional dynamics materially influence regulatory pathways, supply chain design, and commercial approaches for lornoxicam tablets. In the Americas, market access is shaped by diverse payer landscapes, stringent pharmacovigilance expectations, and a mix of public and private procurement processes that require tailored market entry tactics and clear evidence of therapeutic value. Distribution channels in this region vary from centralized hospital purchasing to robust retail pharmacy networks, necessitating differentiated engagement and logistics models.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous national requirements, which creates both opportunities for consolidated submissions and challenges in local compliance. Public tendering remains a key route to institutional adoption in several countries, and private healthcare segments can present distinct commercial pathways that emphasize supplier reliability and cost-containment. The region also exhibits significant variance in infrastructure and cold chain capabilities, which affects distribution planning.

In Asia-Pacific, rapid digital adoption of healthcare services and accelerating investment in manufacturing capacity are shaping access models. Online pharmacy growth and mobile-enabled distribution are particularly pronounced in several markets, increasing the importance of digital engagement strategies and flexible packaging formats. Regional supply networks and trade agreements also influence sourcing choices and time-to-market considerations.

Understanding these regional nuances enables manufacturers and distributors to align regulatory submissions, channel strategies, and supply solutions with local market realities, thereby reducing commercial friction and improving adoption potential for lornoxicam tablets across diverse geographic contexts.

Competitive company behaviors and differentiators shaped by clinical evidence investments, channel alignment, and supply chain resilience strategies

Competitive positioning among companies active in the lornoxicam tablets domain reflects investments in clinical evidence, regulatory compliance, distribution partnerships, and manufacturing flexibility. Leading organizations emphasize robust pharmacovigilance infrastructures and clear labeling that supports safe use across indicated conditions. They also pursue channel-specific strategies, forming alliances with hospital procurement groups, retail chains, and digital pharmacy platforms to secure multi-channel presence and ensure product availability at the point of care.

Several companies focus on packaging innovation and patient adherence initiatives, deploying blister packs or multidose bottle formats in response to clinician and patient preferences. Others invest in supply chain redundancy through geographically diverse manufacturing or dual-sourcing arrangements to mitigate disruption risks. In parallel, established players leverage medical affairs and field engagement to communicate differentiated value propositions to prescribers managing ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis.

Newer entrants often seek to disrupt traditional models by partnering with technology-enabled pharmacies or offering value-added services such as digital adherence tools and clinician support programs. Across all firm types, cross-functional coordination between regulatory, commercial, and supply teams is a common success factor. Companies that integrate clinical evidence generation with pragmatic distribution and pricing strategies are best positioned to sustain access and adoption in complex healthcare environments.

Actionable recommendations for commercial, regulatory, and supply chain leaders to secure access, ensure compliance, and drive adoption of lornoxicam tablets

Industry leaders can take concrete actions to strengthen competitive positioning and ensure sustainable access to lornoxicam tablets. First, align pharmacovigilance and regulatory strategies with product lifecycle milestones to preemptively address safety queries and support label maintenance. This proactive stance reduces time to resolution for regulatory requests and builds confidence among healthcare purchasers and clinicians.

Second, pursue channel-specific commercialization plans that reflect the distinct operational realities of hospital pharmacies, online platforms, and retail outlets. Tailored contracting, distributor relationships, and digital engagement programs will enhance availability and appropriate use across endpoints of care. Third, optimize packaging selection and patient support initiatives to improve adherence and reduce dispensing errors; evaluate blister pack and bottle formats in relation to typical dosing strengths and user settings.

Fourth, incorporate tariff scenario planning into procurement and sourcing decisions to preserve margin and reliability in the face of policy shifts. Fifth, foster closer collaboration between clinical affairs, supply chain, and commercial teams to translate evidence into actionable promotional and access strategies. Finally, invest selectively in regional capabilities and partnerships that reflect local regulatory regimes and distribution infrastructures. These coordinated actions will help organizations convert clinical value into durable market access and operational resilience.

Robust mixed-methods research methodology integrating primary stakeholder insights, secondary evidence synthesis, and cross-functional validation to ensure analytical rigor

This research applies a mixed-methods approach that integrates primary qualitative interviews, secondary literature synthesis, and cross-functional validation to construct a comprehensive view of the lornoxicam tablet landscape. Primary inputs include structured engagements with clinicians, hospital pharmacists, procurement professionals, and channel operators to surface operational challenges, prescribing rationales, and distribution preferences. These perspectives are then triangulated with regulatory documents, clinical literature, and publicly available policy guidance to ensure factual accuracy and contextual relevance.

Data collection emphasizes reproducible classification of products by dosage strength, indication, distribution channel, end user, and packaging type to support coherent segmentation analysis. Supply chain and tariff implications are examined through dialogue with sourcing and logistics experts, while regional insights draw on localized regulatory and distribution knowledge. Throughout the process, cross-validation workshops were conducted to reconcile divergent viewpoints and to stress-test assumptions about channel dynamics and stakeholder priorities.

Transparency is maintained through clear documentation of sources and engagement protocols, and analytical frameworks prioritize clinical relevance, operational feasibility, and strategic applicability. This methodology ensures that recommendations are grounded in practitioner experience and augmented by objective secondary evidence, thereby providing practical guidance for stakeholders navigating the lornoxicam tablet environment.

Concluding strategic synthesis emphasizing integration of clinical evidence, regional nuance, and operational resilience to guide lornoxicam tablet decision making

In conclusion, the lornoxicam tablet landscape demands an integrated approach that bridges clinical evidence, regulatory preparedness, channel strategy, and supply chain resilience. Stakeholders who synthesize pharmacologic understanding with pragmatic distribution planning and adaptive commercial models will be better equipped to meet clinician expectations and patient needs. Strategic packaging and dosing considerations, aligned with targeted engagement across hospital, online, and retail channels, will influence adoption patterns and support appropriate use.

Regional nuances underscore the importance of tailored market access plans that respect local regulatory regimes and distribution capacities. Meanwhile, tariff environments and policy shifts necessitate proactive procurement and sourcing strategies to preserve operational continuity. Competitive differentiation will increasingly reflect an organization's ability to coordinate medical affairs, regulatory compliance, and logistics, while also delivering practical support that improves adherence and patient outcomes.

Ultimately, the most successful stakeholders will be those who anticipate change, prioritize cross-functional collaboration, and invest in evidence and infrastructure that aligns clinical value with commercial execution. This conclusion frames the strategic choices that emerge from the research and points toward the operational actions required to translate insights into measurable improvements in access and therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lornoxicam Tablets Market, by Dosage Strength

  • 8.1. 4 Mg
  • 8.2. 8 Mg

9. Lornoxicam Tablets Market, by Indication

  • 9.1. Ankylosing Spondylitis
  • 9.2. Osteoarthritis
  • 9.3. Rheumatoid Arthritis

10. Lornoxicam Tablets Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. Lornoxicam Tablets Market, by Packaging Type

  • 11.1. Blister Packs
  • 11.2. Bottles

12. Lornoxicam Tablets Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lornoxicam Tablets Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lornoxicam Tablets Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Lornoxicam Tablets Market

16. China Lornoxicam Tablets Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ambica Pharma
  • 17.6. AstraZeneca Pharma India Ltd
  • 17.7. Aurobindo Pharma
  • 17.8. Bayer AG
  • 17.9. Biodef Health Care Private Limited
  • 17.10. Cipla Ltd
  • 17.11. Dr. Reddy's Laboratories
  • 17.12. Glenmark Pharmaceuticals
  • 17.13. IPCA Laboratories Ltd
  • 17.14. Johnlee Pharmaceuticals Pvt. Ltd.
  • 17.15. Laurus Labs Ltd
  • 17.16. Lupin Ltd
  • 17.17. Ocean Pharmaceutical
  • 17.18. Orley Laboratories Pvt Ltd
  • 17.19. Pfizer Ltd
  • 17.20. Ronak Lifecare Pvt Ltd
  • 17.21. Sandoz International GmbH
  • 17.22. Shreeji Pharma International
  • 17.23. Sun Pharmaceutical Industries Ltd
  • 17.24. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LORNOXICAM TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LORNOXICAM TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 4 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 4 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 4 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 8 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 8 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY 8 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BLISTER PACKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BLISTER PACKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS LORNOXICAM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA LORNOXICAM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GCC LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 85. GCC LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GCC LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. G7 LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 100. G7 LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. G7 LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. NATO LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NATO LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LORNOXICAM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA LORNOXICAM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA LORNOXICAM TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA LORNOXICAM TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA LORNOXICAM TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA LORNOXICAM TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)